Sensei Biotherapeutics Statistics
Total Valuation
SNSE has a market cap or net worth of $9.72 million. The enterprise value is -$27.77 million.
Important Dates
The next estimated earnings date is Thursday, May 8, 2025, before market open.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
SNSE has 25.21 million shares outstanding. The number of shares has decreased by -10.14% in one year.
| Current Share Class | 25.21M |
| Shares Outstanding | 25.21M |
| Shares Change (YoY) | -10.14% |
| Shares Change (QoQ) | +0.08% |
| Owned by Insiders (%) | 2.30% |
| Owned by Institutions (%) | 9.38% |
| Float | 16.55M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.25 |
| P/TBV Ratio | 0.25 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.70, with a Debt / Equity ratio of 0.10.
| Current Ratio | 7.70 |
| Quick Ratio | 7.59 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -344.03 |
Financial Efficiency
Return on equity (ROE) is -58.40% and return on invested capital (ROIC) is -34.15%.
| Return on Equity (ROE) | -58.40% |
| Return on Assets (ROA) | -32.32% |
| Return on Invested Capital (ROIC) | -34.15% |
| Return on Capital Employed (ROCE) | -77.58% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.01M |
| Employee Count | 15 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -60.49% in the last 52 weeks. The beta is 0.20, so SNSE's price volatility has been lower than the market average.
| Beta (5Y) | 0.20 |
| 52-Week Price Change | -60.49% |
| 50-Day Moving Average | 0.42 |
| 200-Day Moving Average | 0.51 |
| Relative Strength Index (RSI) | 49.22 |
| Average Volume (20 Days) | 511,311 |
Short Selling Information
The latest short interest is 523,722, so 2.08% of the outstanding shares have been sold short.
| Short Interest | 523,722 |
| Short Previous Month | 1.91M |
| Short % of Shares Out | 2.08% |
| Short % of Float | 3.16% |
| Short Ratio (days to cover) | 0.07 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -30.96M |
| Pretax Income | -29.67M |
| Net Income | -30.16M |
| EBITDA | -29.64M |
| EBIT | -30.96M |
| Earnings Per Share (EPS) | -$1.20 |
Full Income StatementBalance Sheet
The company has $41.34 million in cash and $3.85 million in debt, giving a net cash position of $37.49 million or $1.49 per share.
| Cash & Cash Equivalents | 41.34M |
| Total Debt | 3.85M |
| Net Cash | 37.49M |
| Net Cash Per Share | $1.49 |
| Equity (Book Value) | 38.39M |
| Book Value Per Share | 1.52 |
| Working Capital | 36.48M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$24.67 million and capital expenditures -$146,000, giving a free cash flow of -$24.82 million.
| Operating Cash Flow | -24.67M |
| Capital Expenditures | -146,000 |
| Free Cash Flow | -24.82M |
| FCF Per Share | -$0.98 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |